A5057361309- Platelet Disorders and Treatments
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Blood groups and transfusion
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Blood properties and coagulation
- Autoimmune Bullous Skin Diseases
- Long-Term Effects of COVID-19
- Immunodeficiency and Autoimmune Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Hemophilia Treatment and Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Liver Disease Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Renal Diseases and Glomerulopathies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Radioactivity and Radon Measurements
- Pneumocystis jirovecii pneumonia detection and treatment
- Transplantation: Methods and Outcomes
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 and healthcare impacts
- Hepatocellular Carcinoma Treatment and Prognosis
Vall d'Hebron Hospital Universitari
2014-2024
Banc de Sang i Teixits
2018-2024
Vall d'Hebron Institute of Oncology
2023-2024
Universitat Autònoma de Barcelona
2024
Hospital Universitari Sagrat Cor
2018-2023
Hospital Universitari Sant Joan de Reus
2023
Hebron University
2023
Hospital General de Catalunya
2023
Hospital Quirónsalud Sagrado Corazón
2022
Universidad Nacional Autónoma de México
2020
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment withdrawn but the frequency of this phenomenon unknown. We retrospectively evaluated 260 adult primary ITP (165 women 95 men; median age, 62 years) treated with eltrombopag after a time from diagnosis 24 months. Among 201 who achieved complete remission (platelet count >100 × 10(9) /l), was discontinued 80 patients. Reasons for discontinuation were: persistent...
Summary The thrombopoietin receptor agonists ( THPO ‐ RA s), romiplostim and eltrombopag, are effective safe in immune thrombocytopenia ITP ). However, the value of their sequential use when no response is achieved or adverse events occur with one has not been clearly established. Here we retrospectively evaluated 51 primary adult patients treated followed by eltrombopag. median age our cohort was 49 (range, 18–83) years. There were 32 women 19 men. duration before switching to eltrombopag...
Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens practice. We evaluated the efficacy safety of eltrombopag primary ITP a real-world setting.A total 164 patients with from 40 Spanish centers, who had been treated eltrombopag, were retrospectively evaluated.The median age our cohort (72% women) was 63 yr (interquartile range, IQR, 45-75 yr). The time diagnosis 81 months (IQR, 30-192 months). number...
Summary Eltrombopag is a second‐line treatment in primary immune thrombocytopenia ( ITP ). However, its role secondary unknown. We evaluated the efficacy and safety of eltrombopag daily clinical practice. Eighty‐seven patients (46 with to autoimmune syndromes, 23 neoplastic disease subtype: lymphoproliferative disorders [ LPD s] 18 viral infections) who had been treated were retrospectively evaluated. Forty‐four (38%) platelet response, including 40 (35%) complete responses. Median time...
The increased life expectancy in patients with hemophilia (PwH) over the last years has raised incidence of comorbidities, including thromboembolic events. Thromboembolic events are rare PwH and most them occur presence exogenous risk factors. There is still scarce scientific evidence on optimal antithrombotic treatment management approach this population.
Summary Eltrombopag (ELT) is a thrombopoietin‐receptor agonist that stimulates platelet (PLT) production in patients with primary immune thrombocytopenia (ITP). One potential mechanism of ELT modulating the inflammatory response by increasing PLTs binding to leucocytes. This study examined effect on leucocyte–PLTs complexes 38 ITP patients. Patients, predominantly females mean age 59 years, underwent treatments like corticosteroids, intravenous immunoglobulin and splenectomy. Compared...
Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror practice reality. Here we evaluated eltrombopag primary and secondary ITP in our ≥65-year-old population.A total 106 patients (16 with newly diagnosed ITP, 16 persistent 74 chronic ITP) 39 (20 to disorders, 7 infectious diseases, 12 lymphoproliferative disorders [LPD]) were retrospectively evaluated.Median age cohort was 76 (interquartile range, IQR, 70-81) years. 75.9%...
Objective During the first wave of SARS-CoV-2 pandemic, management anticoagulation therapy in hospitalized patients with atrial fibrillation (AF) was simplified to low-molecular-weight heparin (LMWH) followed by oral anticoagulation, mainly owing risk drug–drug interactions. However, not all anticoagulants carry same risk. Methods Observational, retrospective, and multicenter study that consecutively included AF anticoagulated LMWH or edoxaban concomitantly empirical COVID-19 therapy....
Gastrointestinal bleeding (GIB) is a common adverse event related to anticoagulation therapy. However, evidence comparing the severity, etiology and outcome of GIB in patients taking direct oral anticoagulants (DOAC) vs. vitamin K antagonists (VKA) scarce.To evaluate outcomes under DOACs compared VKA.Patients anticoagulant therapy admitted emergency department with acute were prospectively recruited from July 2016 January 2018 at tertiary referral hospital. Demographic clinical obtained...
AbstractAbstractObjective To describe the clinical profile, risk of complications and impact anticoagulation in COVID-19 hospitalized patients, according to presence atrial fibrillation (AF).Methods Multicenter, retrospective, observational study that consecutively included patients >55 years admitted with from March October 2020. In AF was chosen based on clinicians’ judgment. Patients were followed-up for 90 days.Results A total 646 included, whom 75.2% had AF. Overall, mean age 75 ± 9.1...
Conclusion(s): Direct inhibitors of activated factor X administration significantly affects the determination antithrombin by AT (Xa) method.At higher levels drug, determined level reached normal range and thus thrombophilic state was underestimated.If patient with mentioned deficiency is treated Apixaban, it more appropriate to use method (IIa) or laboratory methodology a DOAC stop tablet for control.
Background: Primary immune thrombocytopenia (ITP) is an autoimmune acquired disease characterized by low production and increased platelet destruction. Thrombopoietin receptor agonists (TPO-RAs) i.e. eltrombopag, romiplostim avatrombopag are currently used as second line treatment for ITP. Eltrombopag has demonstrated high response rates (≥80%) both in clinical trials routine practice studies. Nevertheless, some patients refractory to this drug do not attain a when using the maximum...